This article was originally published in The Gray Sheet
FDA approves Sept. 14, 1994 petition by W.L. Gore and Associates to reclassify nonabsorbable expanded polytetrafluoroethylene (ePTFE) surgical sutures for soft tissue approximation and ligation from Class III to Class II, effective May 18. As a special control, the device is labeled for "single use only" and contraindicated for ophthalmic and neural tissues, according to an April 18 Federal Register notice
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.